Answers are grounded in this paper and cite their sources.
Irreversible electroporation (IRE) has emerged as a potential therapeutic option that selectively ablates cancer cells in the prostate while preserving normal tissue architecture and minimizing adverse effects. However, IRE-induced cell death triggers an inflammatory response that promotes collagen deposition, leading to fibrotic tissue remodeling. This study investigated the efficacy and safety of combination therapy using IRE and a transforming growth factor-β (TGF-β) type I receptor kinase (ALK5) inhibitor in a human prostate cancer xenograft mouse model, with focus on whether ALK5 inhibitor could mitigate excessive fibrosis while preserving the anti-tumor effect of IRE. EW-7197, a specific ALK5 inhibitor, effectively suppressed cell proliferation and fibrogenesis in vitro. A total of 24 mice inoculated with DU145-Luc cells were enrolled. Tumor progression was monitored via in vivo imaging system, magnetic resonance imaging, and gross examination, and the anti-tumor and anti-fibrotic effects were assessed through histological analysis. The tumor suppression-related parameters in the IRE and IRE@EW-7197 groups were significantly lower than those in the control and EW-7197 groups (all p < 0.05). The IRE@EW-7197 group showed the greatest numerical reduction in tumor volume without statistical difference compared with the IRE group. Fibrosis-related markers were significantly suppressed in the EW-7197 and the IRE@EW-7197 groups. These findings suggest that ALK5 inhibition attenuated excessive fibrosis and modulated the inflammatory response without compromising the short-term anti-tumor efficacy of IRE. The combination therapy may represent a promising strategy to mitigate IRE-induced fibrosis in prostate cancer, although longer-term studies are needed to determine whether it confers additional oncologic benefit.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: